Diabetes drugs, especially the glucagon-like peptide-1 (GLP-1) medicines, drove sales at Novo Nordisk A/S to their highest level in five years giving a significant boost to both operating and net profits. Announcing its 2022 financial results on 1 February, the Danish company declared a total dividend for the year of DKK 12.40, up by 19% from a year earlier.
Net sales in 2022 were DKK 176.9 billion ($25.4 billion), up by 26%. At constant exchange rates the increase was 16%. Operating profit was DKK 74.8 billion, up by 28%, and represented 42.3% of sales.